BioSpace News Archive

Business

Owens & Minor Reports Second Quarter 2023 Financial Results

Owens & Minor, Inc. reported financial results for the second quarter ended June 30, 2023.

August 4, 2023
·
23 min read
Business

Newron Announces H1 2023 Results and Provides R&D Update

Newron Pharmaceuticals S.p.A. today announced its financial results and operational highlights for the half year ended June 30, 2023, and provided an update on its R&D and business activities.

August 4, 2023
·
12 min read
Business

Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Precision BioSciences, Inc. today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

August 4, 2023
·
16 min read
Pharm Country

Palatin to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

Palatin Technologies, Inc. today announced that management will participate at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023.

August 4, 2023
·
1 min read
Lilly’s Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy

Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed – with or without pembrolizumab .

August 4, 2023
·
15 min read
Business

Faron Pharmaceuticals Notice of Half-Year Financial Results

Faron Pharmaceuticals Ltd will report its unaudited half-year financial results for the six months ended June 30, 2023, on Tuesday, August 29, 2023.

August 4, 2023
·
5 min read
Pharm Country

Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference

Intra-Cellular Therapies, Inc. today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 1:30 p.m. ET.

August 4, 2023
·
1 min read
Business

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.

August 4, 2023
·
13 min read
Business

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

Belite Bio, Inc today announced that it will host a live webcast on Wednesday, August 9, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results for the second quarter ended June 30, 2023.

August 4, 2023
·
1 min read
Policy

Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that it has submitted a New Drug Application to the US Food and Drug Administration.

August 4, 2023
·
6 min read